WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that results from a Phase 2 clinical trial of its vascular disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin), in women with platinum-resistant ovarian cancer, will be presented in a symposium at the upcoming 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, FL, June 1, 2009. In addition, an abstract describing clinical results from an ongoing Phase 1 trial in solid tumors of OXi4503, the Company's second-generation, dual-mechanism drug candidate, is published in the ASCO meeting program. OXiGENE will release a summary of presented results on June 1, 2009.
